Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06850623 · ClinicalTrials.gov registry record · Phase 2

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

A Phase 2 study of Locally Advanced Pancreatic Adenocarcinoma, sponsored by EXACT Therapeutics AS.

Recruiting
Registry status
Phase 2
Development phase
25
Enrollment target
10
Study locations

NCT06850623 is a Phase 2 study of Locally Advanced Pancreatic Adenocarcinoma that is actively recruiting participants, run by EXACT Therapeutics AS. The registered enrollment target is 25 participants, below the 66-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (62% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06850623, a Phase 2 study of Locally Advanced Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by EXACT Therapeutics AS.

RECRUITING
Registry status
Phase 2
Development phase
25 participants
Enrollment target
10
Study locations

Study Summary

The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.

Conditions Studied

Locally Advanced Pancreatic Adenocarcinoma

Interventions

  • DRUG Modified FOLFIRINOX
  • COMBINATION_PRODUCT Acoustic Cluster Therapy

Study Locations (10)

Pennsylvania

  • Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital - Philadelphia
  • Allegheny General Hospital - Pittsburgh

Arizona

  • HonorHealth Research Institute - Scottsdale

California

  • Stanford Cancer Center Palo Alto - Stanford

Massachusetts

  • Beth Israel Deaconess Medical Center - Division of Hematology/Oncology - Boston

Michigan

  • Henry Ford Centre - Detroit

Rhode Island

  • Brown University Cancer Institute - Providence

Cambridge

  • CAMBRIDGE CANCER TRIALS CENTRE-Addenbrooke's Hospital - Cambridge

London

  • Gary Weston Centre- Imperial College Healthcare- Du Cane Road - Hammersmith

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2025-06-19
Est. Completion 2027-07-15
Phase Phase 2

Sponsor

EXACT Therapeutics AS

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06850623

The ClinicalTrials.gov registry entry for NCT06850623 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (62% lower). The listed sponsor is EXACT Therapeutics AS, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Locally Advanced Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Modified FOLFIRINOX is the first listed.

NCT06850623 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Pennsylvania, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT06850623 about?

NCT06850623 is a clinical study titled "Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer". The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.

What is the current status of trial NCT06850623?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-06-19. Estimated completion is 2027-07-15.

What conditions does trial NCT06850623 study?

This clinical trial studies the following conditions: Locally Advanced Pancreatic Adenocarcinoma.

What interventions are being tested in trial NCT06850623?

The interventions under investigation include: Modified FOLFIRINOX (DRUG), Acoustic Cluster Therapy (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06850623?

This trial is sponsored by EXACT Therapeutics AS, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06850623 being conducted?

This trial has 10 study locations across Arizona, California, Massachusetts, Michigan, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Locally Advanced Pancreatic Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Locally Advanced Pancreatic Adenocarcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.